Thursday March 28, 2024 | Last Update: March 28, 2024 EDT
BioMarin Pharmaceuticals Inc. has announced in a press release that the U.S. Food and Drug Administration (FDA) will be delaying its decision on the company’s new drug application.
Read more >>
Amgen Inc. has announced in a press release the submission of a Biologics License Application to the U.S. Food and Drug Administration (FDA) for ABP 501, a biosimilar candidate to Humira, or adalimumab, an anti-TNF-α monoclonal antibody. The application is Amgen’s first Biologics License Application submitted using the 351 (k) biosimilar pathway.
Just In
Most Read
1